Drug development


HBM contact: Dr Ivo Staijen, Dr Emil Bujak

Company status: public

AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company developing first-in-class antibody product candidates focused on unmet medical needs in inflammation. AnaptysBio harnesses its proprietary antibody library to select antibodies against clinically relevant targets. Lead asset is in Phase 2 in Allergy/Autoimmunity covering indications such as Peanut allergy, Atopic dermatitis and Psoriasis. The company has a number of partnerships with biotechs such as Celgene and Tesaro.

© HBM Partners AG  |  Bundesplatz 1  |  6300 Zug, Switzerland  |  Phone  +41 43 888 7171